Eligible pts had non-hematological malignancies for which standard therapy did not exist or was no longer effective and HER2 overexpressing tumors. IL-2 was initially administered at a dose of 1.25 million IU/m2 (low dose) s.c. Daily. TRZ was administered i.v. just before the first intermediate IL-2 dose and was escalated in cohorts of 6 or more pts. Here, ERBB2 is linked to hematologic disorder.